STSS vs. NEPH, PYPD, LFWD, LUCY, IINN, LYRA, SSKN, CTCX, QTI, and BTCY
Should you be buying Sharps Technology stock or one of its competitors? The main competitors of Sharps Technology include Nephros (NEPH), PolyPid (PYPD), ReWalk Robotics (LFWD), Innovative Eyewear (LUCY), Inspira Technologies Oxy B.H.N. (IINN), Lyra Therapeutics (LYRA), STRATA Skin Sciences (SSKN), Carmell (CTCX), QT Imaging (QTI), and Biotricity (BTCY). These companies are all part of the "medical equipment" industry.
Sharps Technology vs.
Nephros (NASDAQ:NEPH) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.
Nephros currently has a consensus target price of $5.00, indicating a potential upside of 212.50%. Given Nephros' stronger consensus rating and higher possible upside, equities analysts clearly believe Nephros is more favorable than Sharps Technology.
In the previous week, Nephros' average media sentiment score of 0.00 equaled Sharps Technology'saverage media sentiment score.
Nephros has higher revenue and earnings than Sharps Technology. Nephros is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.
Nephros received 12 more outperform votes than Sharps Technology when rated by MarketBeat users. However, 100.00% of users gave Sharps Technology an outperform vote while only 43.33% of users gave Nephros an outperform vote.
Nephros has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.
Sharps Technology has a net margin of 0.00% compared to Nephros' net margin of -6.86%. Nephros' return on equity of -11.39% beat Sharps Technology's return on equity.
41.1% of Nephros shares are held by institutional investors. Comparatively, 17.2% of Sharps Technology shares are held by institutional investors. 4.1% of Nephros shares are held by insiders. Comparatively, 8.7% of Sharps Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Nephros beats Sharps Technology on 10 of the 14 factors compared between the two stocks.
Get Sharps Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for STSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sharps Technology Competitors List
Related Companies and Tools
This page (NASDAQ:STSS) was last updated on 1/21/2025 by MarketBeat.com Staff
